Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it has received CNY 999.999985 million in funding from a group of investors
January 28, 2021
Share
On January 29, 2021, Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) closed the transaction. The company has issued 26,171,159 common shares at a issue price of CNY 38.21 per share for gross proceeds of CNY 999,999,985.39 in the transaction. The number of shares increased from 805,234,971 shares to 831,406,130 shares upon closing. The transaction included participation from Lombarda China Fund Management Co., Ltd. for 9,604,822 shares, JT Asset Management Co., Ltd. for 2,643,287 shares, Dacheng Fund Management Company Limited for 1,936,665 shares, China Petrochemical Corporation, Enterprise Annuity Plan for 1,360,900 shares, Enterprise Annuity Plan Of China Mobile Communications Corporation for 1,360,900 shares, Changjiang Pension Insurance Co., Ltd. .- China Pacific Life Insurance Private Placement (Dividends) Trust Investment Management Account for 1,360,900 shares, UBS AG for 1,308,557 shares, Ronghui Asset Management Plan No.1, a fund managed by First Seafront Fund Management Co., Ltd. for 1,308,557 shares, Taiping Assets Private Placement No. 18 (Liding) Management Plan, a fund managed by Taiping Asset Management Company Limited for 1,308,557 shares, Shanghai No. 4 Occupational Annuity Plan-Shanghai Pudong Development Bank for 1,360,900 shares, Hualing Jinshan (Tianjin) Industry Investment Fund Partnership Enterprise (L.P.), a fund managed by Valin Jinshan Industrial Investment Management Co., Ltd. for 1,308,557 shares, and Yangtze River Jinsejiaoxiang (Collective) Enterprise Annuity Plan-Bank of Communications Co., Ltd. for 1,308,557 shares. The company paid tax expenses of CNY 9,380,611.68 in the transaction.
Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The New Drug and Intermediates CDMO segment mainly provides services for innovative medicines of pre-clinical chemical manufacturing and controls (CMC), clinical phases I, II and III, new drug application (NDA) and various stages after going public. The Specialty API and Intermediates segments mainly provides services including patent breakthroughs, production process improvement, drug certificate declaration, and cGMP standard commercial production for patented expired or soon-to-be-expired drugs for global chemical and generic drug manufacturers.
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD 
